Rubicon Research Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Rubicon Research Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $11.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Rubicon Research Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $11.1M Trade | TransData Nexus

Rubicon Research Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $11.1M Total Trade · DGFT Verified

Rubicon Research Limited is an Indian pharmaceutical exporter with a total trade value of $11.1M across 8 products in 4 therapeutic categories. Based on 357 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metoprolol ($4.4M), Carvedilol ($2.0M), Clonazepam ($1.8M).

Rubicon Research Limited — Export Portfolio & Destination Treemap

Rubicon Research Limited pharmaceutical export portfolio — 8 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Rubicon Research Limited? — Company Overview & Market Position

Rubicon Research Limited, established on May 6, 1999, is a publicly listed pharmaceutical company headquartered in Thane, Maharashtra, India. The company specializes in the development, manufacturing, and commercialization of generic and specialty pharmaceutical formulations. Its product portfolio spans various therapeutic categories, including cardiovascular, central nervous system (CNS), and antimalarial treatments. Rubicon Research Limited is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 544578 and on the National Stock Exchange of India (NSE) under the ticker symbol RUBICON.

The company's authorized capital is ₹23.90 crore, with a paid-up capital of ₹16.48 crore. As of the latest available data, Rubicon Research Limited employs approximately 827 professionals. The corporate office is located at MedOne House, B-75, Road No. 33, Wagle Estate, Thane (West), Maharashtra 400604, India.

What Does Rubicon Research Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metoprolol$4.4M 2

Product Portfolio — Top 8 by Export Value

Rubicon Research Limited exports 8 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metoprolol	Cardiovascular	$4.4M	97	0.5%	13
2	Carvedilol	Cardiovascular	$2.0M	69	2.1%	10
3	Clonazepam	CNS & Psychiatric	$1.8M	69	1.4%	3
4	Amiodarone	Cardiovascular	$1.0M	25	1.4%	7
5	Isosorbide	Cardiovascular	$993.3K	23	2.2%	7
6	Ivermectin	Antimalarial & Antiparasitic	$300.0K	6	3.5%	4
7	Ipratropium	Respiratory	$292.3K	54	0.5%	7
8	Nitroglycerin	Cardiovascular	$176.4K	14	1.8%	10

Rubicon Research Limited exports 8 pharmaceutical products across 4 therapeutic categories with a total export value of $11.1M. The top category is Cardiovascular (78.2% of portfolio), followed by CNS & Psychiatric (16.5%), indicating a concentrated portfolio with the top 5 products accounting for 93.0% of total export value.

Rubicon Research Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Rubicon Research Limited operates multiple manufacturing facilities in India, including plants in Ambernath, Satara, and Pithampur. The Ambernath facility, commissioned in 2009, specializes in the production of oral solid dosage forms. In 2021, the company acquired the oral liquid dosage and nasal product manufacturing facility of Meditab Specialities Limited in Satara, Maharashtra. Additionally, in 2025, Rubicon Research Limited acquired the Pithampur manufacturing facility from Alkem Laboratories Ltd.

3Key Leadership

The leadership team at Rubicon Research Limited includes:

Parag Suganchand Sancheti: Chief Executive Officer (CEO) since May 9, 2019.

Pratibha Sudhir Pilgaonkar: Managing Director since June 1, 2000.

Anand Agarwal: Nominee Director since January 3, 2025.

Changavalli Venkat: Director since June 11, 2024.

Varun Talukdar: Director since September 5, 2023.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Rubicon Research Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Rubicon Research Limited has established a significant presence in regulated markets, particularly in the United States. The company has obtained Good Manufacturing Practice (GMP) certifications for its facilities in Ambernath and Satara, Maharashtra, enabling it to manufacture and export pharmaceutical products to the U.S. and European markets. Additionally, Rubicon Research Limited has received approvals for over 28 products in the U.S. market, demonstrating its compliance with stringent regulatory standards.

2Emerging Markets

Rubicon Research Limited has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's acquisition of Impopharma Canada Ltd. in 2019, which specializes in pulmonary and nasal drug delivery systems, ophthalmic, otic, and dermal products, has enhanced its capabilities to serve these regions. Furthermore, the establishment of Rubicon Consumer Healthcare in 2020 indicates a strategic focus on developing healthcare and personal wellness solutions tailored for the Indian market.

3Geographic Strategy

Rubicon Research Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Rubicon Research Limited's manufacturing facilities in Ambernath and Satara, Maharashtra, are registered with the U.S. Food and Drug Administration (FDA), allowing the company to export pharmaceutical products to the U.S. market. The company has received approvals for over 28 products in the U.S., demonstrating its compliance with FDA standards. Additionally, Rubicon Research Limited has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, reflecting its commitment to expanding its product offerings in the U.S. market.

2WHO & EU GMP

Rubicon Research Limited's manufacturing facilities have been inspected and approved by the World Health Organization (WHO) and the European Medicines Agency (EMA), ensuring compliance with international Good Manufacturing Practice (GMP) standards. These certifications facilitate the company's ability to export pharmaceutical products to various global markets, including Europe and other regions that recognize WHO and EU GMP standards.

3CDSCO & Indian Regulatory

Rubicon Research Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Rubicon Research Limited operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's focus on specialized drug delivery technologies and a diverse product portfolio positions it favorably against competitors. The acquisition of Impopharma Canada Ltd. and the establishment of subsidiaries like Rubicon Consumer Healthcare and Rubicon Academy further enhance its competitive edge by expanding its product offerings and market reach.

2Key Differentiators

Rubicon Research Limited's key differentiators include its proprietary drug delivery technologies, such as RubiSRL for sustained release liquids and RubiReten for gastro-retentive systems. The company's extensive patent portfolio, with over 50 patents in drug delivery technologies, underscores its commitment to innovation. Additionally, the acquisition of Impopharma Canada Ltd. has expanded its capabilities in pulmonary and nasal drug delivery systems, ophthalmic, otic, and dermal products, further distinguishing its product offerings.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Rubicon Research Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Rubicon Research Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $11.1 million USD across 357 shipments. The company's portfolio concentration of 93% in its top five products indicates a focused approach to product development and market penetration. The absence of regulatory observations or warnings further attests to its reliability as a supplier. These factors collectively suggest that Rubicon Research Limited is a dependable partner for pharmaceutical procurement.

2Certifications to Verify

Importers should verify the following certifications when considering Rubicon Research Limited as a supplier:

FDA Registration: Confirm the registration of manufacturing facilities with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure that manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice standards.

Frequently Asked Questions — Rubicon Research Limited

How many pharmaceutical products does Rubicon Research Limited export from India?

Rubicon Research Limited exports 8 pharmaceutical products across 4 therapeutic categories. The top exports are Metoprolol ($4.4M), Carvedilol ($2.0M), Clonazepam ($1.8M), Amiodarone ($1.0M), Isosorbide ($993.3K). Total export value is $11.1M.

What is Rubicon Research Limited's total pharmaceutical export value?

Rubicon Research Limited's total pharmaceutical export value is $11.1M, based on 357 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Rubicon Research Limited cover?

Rubicon Research Limited exports across 4 therapeutic categories. The largest are Cardiovascular (78.2%, 5 products), CNS & Psychiatric (16.5%, 1 products), Antimalarial & Antiparasitic (2.7%, 1 products).

Get Full Rubicon Research Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.